ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
Source: Motley Fool
2026-02-20 00:22:22 ET
According to a SEC filing dated February 17, 2026, ORBIMED Advisors LLC sold 5,409,671 shares of Terns Pharmaceuticals (NASDAQ:TERN) , an estimated $125.01 million transaction based on the average closing price for the quarter ending December 31, 2025. The fund finished the period holding 2,153,300 shares, with the value of its position decreasing by $30.20 million, a figure that accounts for both share sales and price changes.
After this sell, the Terns Pharmaceuticals position represents 1.78% of ORBIMED Advisors LLC’s 13F reportable AUM
Top holdings after the filing:
Boston Scientific Corporation
NASDAQ: BSX
BSX Trading
2.68% G/L:
$76.58 Last:
4,792,448 Volume:
$75.27 Open:
BSX Latest News
February 25, 2026 01:00:00 pm
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026 02:32:00 pm
Ongoing Investigation into Boston Scientific Corporation (BSX): Contact Levi & Korsinsky About Potential Fraud
February 23, 2026 08:00:00 am
Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors
February 20, 2026 12:22:22 am
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing
BSX Stock Data
$110,308,512,122
1,467,617,619
0.01%
911
N/A
Medical Equipment & Supplies
Healthcare
US
Marlborough
